The purpose of this study was to determine the plasma pharmacokinetics (PK) and toxicity of zebularine, an oral cytidine analog with demethylating activity, in dogs. Plasma zebularine concentrations were determined by HPLC-MS/MS following an oral zebularine dose of 8 or 4 mg kg −1 . Plasma zebularine clearance was constant. Mean maximum concentration (C max ) was 23 ± 4.8 and 8.6 ± 1.4 μM following 8 and 4 mg kg −1 , respectively. Mean half-life was 5.7 ± 0.84 and 7.1 ± 2.1 following 8 and 4 mg kg −1 , respectively. A single 8 mg kg −1 dose was well tolerated. Daily 4 mg kg −1 treatment in three laboratory dogs resulted in grade 4 neutropenia (n = 3), grade 1 anorexia (n = 2) and grade 1 or 2 dermatologic changes (n = 2). All adverse events resolved with supportive care. A 4 mg kg −1 dose every 21 days was well tolerated. A follow-up dose escalation study is in progress with a lower starting dose.
Introduction
DNA methylation is an important epigenetic modification that often occurs on cytosines within cytosine guanine dinucleotides (CpGs). 1, 2 CpGs are concentrated within gene promoter regions in half of all human genes. 1 Hypermethylation of DNA within the promoter region of a tumor suppressor gene can result in functional silencing of the gene and an increased risk of cancer development or progression. 1 -3 DNA methylation patterns are maintained by DNA methyltransferases (DNMTs) during DNA replication. Unlike genetic mutations, epigenetic changes are potentially reversible. 1, 2 Zebularine [1--D-ribofuranosyl-2(1H)-pyrimidinone] is a cytidine analog that was originally identified as a bacteriostatic drug, then determined to be a cytidine deaminase (CDA) inhibitor and more recently determined to be a DNMT inhibitor. 2, 3 Zebularine is incorporated into DNA in place of cytidine and forms a complex with DNMTs, thus inhibiting methylation. The mechanism of action of zebularine's demethylating activity is similar to that of 5-azacytidine (Vidaza ® , Celgene Corp., Summit, NJ, USA; 5-Aza-CR) and decitabine (Dacogen ® , Eisai, Woodcliff Lake, NJ, USA; 5-Aza-CDR), which are currently FDA approved for the treatment of human cancers.
in vitro, which may be due to inhibition of DNA repair. 4, 5 Dogs with naturally occurring cancer offer an excellent opportunity to evaluate and optimize new cancer treatment strategies including those involving demethylating agents. 6, 7 The injectable DNMT inhibitor 5-Aza-CR has been investigated in dogs with invasive transitional cell carcinoma (InvTCC) of the urinary bladder with promising results. Subcutaneous injections were administered daily for five consecutive days at 2-or 4-week intervals in 18 dogs, resulting in 22% partial remission and 50% stable disease for more than 8 weeks. 7 Long term administration of demethylating agents may be required to maintain DNA demethylation. Daily oral administration is likely to be the most convenient dosing strategy, particularly in veterinary patients, making the oral demethylating agent zebularine an attractive drug to investigate in subsequent studies. 8, 9 Previous pharmacokinetic and toxicity assessment of zebularine has been performed in mice, rats and rhesus monkeys. 10 Zebularine administered by intravenous or intraperitoneal injection, oral gavage, or in drinking water was well tolerated in vivo in genetically tumor prone mice, transgenic mice and mice harboring tumor xenografts. Demethylating activity and reactivation of silenced genes correlated with tumor responses including stable disease, delayed or decreased tumor development and decreases in tumor volume compared with untreated control mice. 11 -16 Clinicopathologic evidence of liver and kidney injury were detected in male cynomolgus monkeys after 2 weeks of treatment with intravenous infusions of 250 mg kg −1 for 5 out of 7 days. Further dose elevations to 500, 750 and 1000 mg kg −1 were lethal. 17 Aldehyde oxidase appears to be important in zebularine's metabolism, and may have played a role in the toxicity observed following administration of very high doses of zebularine in cynomologus monkeys. 3 Studies related to the activity of zebularine in canine cells are limited. Previous in vitro studies have included the development of a zebularine plasma protein binding assay performed on samples from Beagle dogs, treatment of canine osteosarcoma cells with zebularine alone or in combination with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA), and treatment of canine malignant lymphoid cell lines with zebularine alone. 10, 18, 19 Treatment with 1 mM zebularine alone or the combination of 10 μM zebularine and 1 μM SAHA resulted in a significant decrease in cell viability in two out of three canine osteosarcoma cell lines. 18 Global DNA methylation, DNMT1 expression and cell survival were significantly decreased, and apoptosis, as measured by caspase 3/7 activity, was significantly increased following treatment of canine malignant lymphoid cells with 200 μM zebularine. 19 In vivo evaluation of zebularine has not been performed in the dog. The purpose of this study was to evaluate the pharmacokinetics (PK) and toxicity associated with oral zebularine administration in laboratory dogs and dogs with naturally occurring cancer. Aldehyde oxidase activity in canine liver cytosol was determined as this enzyme has been implicated in zebularine's metabolism, efficacy and toxicity. 3 Pharmacokinetic parameters for zebularine including area under the curve (AUC), area under the moment curve (AUMC) and the elimination rate constant, k el , were estimated using noncompartmental methods with add-ins on Excel ® . The half-life (t 1/2 ) was estimated by 0.693 k el −1 .
Materials and methods

Study subjects
Zebularine AUC was estimated from time zero to infinity. The AUC from the last concentration, C last , to infinity was estimated by C last k el −1 . The systemic clearance (Cl F −1 , where F is the bioavailability) was calculated from the dose and AUC 0-∞ (area under the plasma concentration-time curve from 0 to infinity) and the volume of distribution at steady state (Vd ss F −1 ) was calculated from the Cl and the mean residence time [MRT; MRT = (Dose/AUC) × (AUMC/AUC)]. The maximum plasma concentration (C max ) and the time of C max (t max ) were obtained from the data. A calibration curve using eight points including a zero (concentrations were 1-1000 ng mL −1 ) was run each day PK samples were run. In addition to the calibration curve, a set of six zebularine quality control (QC) samples (three concentrations in duplicate made from a solution of zebularine that was different from the solution used to make the standards) at low (3 ng mL −1 ), medium (30 ng mL −1 ) and high (800 ng mL −1 ) concentrations were run with each standard curve. The acceptable accuracy of the QC samples based on the calibration curve was set at 80% for the low and the medium QC samples and 85% for the high QC sample. If the accuracy of the QCs was not met for a specific run, the samples were rerun. The inter-day accuracy for five different runs at the low, medium and high QC concentrations ranged from 83 to 91%. The inter-day precision (% coefficient of variation) for the same QC concentrations ranged from 4.7 to 11.9%. The lower limit of quantification (LOQ) was 1 ng mL −1 using 200 μL of plasma.
Zebularine toxicity
Zebularine toxicity was assessed in laboratory dogs receiving a daily oral dose of 4 mg kg −1 . Zebularine toxicity was assessed in tumor bearing dogs receiving an oral dose of 4 mg kg −1 once every 21 days. Zebularine was administered with food to both laboratory and tumor bearing dogs. Toxicity was assessed by physical examination, serial complete blood counts, serial serum biochemistry panels and urinalyses. Physical examinations were performed at least twice daily on laboratory dogs and planned at weekly intervals for tumor bearing dogs. Pet owners were also asked to observe their dogs at home and report any changes that occurred following initiation of treatment. Serial complete blood counts, serum biochemistry panels and urinalyses were scheduled at weekly intervals for laboratory dogs. Serial complete blood counts were scheduled at weekly intervals for the first 6 weeks of treatment and then once every 10 days in tumor bearing dogs. Serum biochemistry panels and urinalyses were scheduled at least once every 3 weeks in tumor bearing dogs. Additional diagnostics were performed as needed based on observed toxicity at the discretion of the attending clinician. Toxicity was graded using the Veterinary Cooperative Oncology Group common terminology criteria for adverse events v1.1 (VCOG-CTCAE v1.1). 20 Treatment was planned for 4 weeks in laboratory dogs. After 4 weeks of treatment, laboratory dogs were to undergo general anesthesia for orchiectomy or ovariohysterectomy and collection of liver and kidney biopsies. Liver and kidney biopsies were evaluated by a board-certified veterinary pathologist to determine if any histologic lesions were present. Liver biopsies were also used to determine aldehyde oxidase activity as described in the next section. Treatment was continued until there was evidence of tumor progression in tumor bearing dogs. Ultrasonography and thoracic radiography were used to monitor for tumor progression in tumor bearing dogs. Abdominal ultrasound or urinary tract ultrasounds were scheduled once every 3 weeks and thoracic radiographs once every 9 weeks until evidence of progression was detected.
Preparation of liver cytosol and measurement of aldehyde oxidase activity
Aldehyde oxidase activity was determined using antemortem liver biopsies obtained from laboratory dogs that had been treated with zebularine, postmortem liver samples obtained from research dogs euthanized for an unrelated project, and a postmortem liver sample from a canine clinical patient euthanized at the PUVTH. All liver samples were snap frozen in liquid nitrogen and maintained at −80 ∘ C until sample processing and analysis was performed.
Preparation of liver cytosol and measurement of aldehyde oxidase activity were performed at the Indiana University School of Public Health, Bloomington, IN, USA. Frozen dog liver tissue (100 mg) was homogenized in 500 μL of 67 mM phosphate buffer containing 1.15% KCl at pH 7.4. The homogenates were then subjected to successive centrifugation at 9000 × g for 20 min and at 100 000 g for 65 min. The cytosolic fractions were collected, aliquoted, and stored at −80 ∘ C until use. Liver samples were obtained from male C57BL/6 or B6C3F1 mice and male F344 rats immediately following euthanasia by carbon dioxide asphyxiation. Mouse and rat liver samples were snap frozen in liquid nitrogen and stored at −80 ∘ C until use. Mouse and rat liver cytosols were prepared concurrently with canine samples for use as controls in the aldehyde oxidase activity assay. The cytosolic protein concentrations were determined using a Pierce bicinchoninic acid protein assay kit (Thermo Scientific, Rockford, IL, USA) with bovine serum albumin as a protein standard.
Aldehyde oxidase activity was measured using benzaldehyde as a substrate. An HPLC-DAD method was developed and validated to measure the decrease amount of substrate consequently upon the oxidation of benzaldehyde to benzoic acid. Briefly, duplicate cytosol samples (260 μg of protein each) from each liver were prepared in 1.5 mL vials. Following the addition of 50 μM benzaldehyde in 0.5 mM sodium phosphate buffer solution containing 0.1 mM EDTA and 1 M NH 4 Cl at pH 7.8 in a total volume of 200 μL at 37 ∘ C, the reaction in one vial was stopped immediately and the other was stopped after 2 min by adding 25 μL of ice-cold 1 N HCl. The reaction mixtures were vortexed and centrifuged at 20 000 × g for 3 min at 4 ∘ C to precipitate proteins; 10 μL of the supernatants were then injected on the HPLC to measure the amount of benzaldehyde. The HPLC system consisted of a Waters Alliance 2695 separation module coupled with Waters 996 Photodiode Array Detector, Waters Corporation, Milford, MA, USA which was controlled by the Empower 2 software. Separation was achieved using a Supelco Discovery HS-C18 (15 cm × 2.1 mm, 3 μm), Supelco, Bellefonte, PA, USA column and a mobile phase that consisted of 50% acetonitrile with a flow rate of 0. 99978. Three concentrations of benzaldehyde were measured six times in 1 day for the intra-day variation. The relative standard variations were 3.3, 1.8 and 0.8% for 2.5, 10 and 50 μM of benzaldehyde, respectively. For inter-day variation determination, the same concentrations of benzaldehyde were measured once daily for 6 consecutive days. The inter-day variations were 7.1, 3.7 and 3.2% for 2.5, 10 and 50 μM benzaldehyde, respectively. In addition, recovery was determined by spiking the same amount of benzaldehyde in a pooled sample matrix. The recoveries were 87.6, 92.3 and 101.1% for 2.5, 10 and 50 μM benzaldehyde, respectively. The limit of detection (LOD) for the aldehyde oxidase activity measurement was 0.0021 nmol mg −1 min −1 and the LOQ was 0.0043 nmol mg −1 min −1 , respectively. The LOD and LOQ were determined using the blank matrix (n = 10). LOD and LOQ were calculated as a mean value of blank matrix signal plus 3 times standard deviation for LOD and 10 times standard deviation for LOQ, respectively.
Results
Study subjects
Three tumor bearing dogs (one 8.7-year-old male neutered Beagle, one 9.6-year-old male neutered mixed breed dog and one 11.3-year-old female spayed Labrador retriever) were enrolled. The dogs weighed 16.9, 27.9 and 30.6 kg, respectively. Two tumor bearing dogs had a histopathological diagnosis of InvTCC, and one had a diagnosis of a recurrent gastrointestinal stromal tumor (GIST). One dog with InvTCC had been previously treated with an NSAID (carprofen) for chronic pain, and the owner elected to continue an NSAID (piroxicam) due to refractory pain at the time of enrollment. One dog with InvTCC had previously failed one injectable chemotherapy drug (vinblastine) and one NSAID (firocoxib). The dog with GIST had undergone surgery to remove the tumor, and the tumor recurred 7 months later at the time zebularine was initiated. PK assessment in tumor bearing dogs was performed following an initial oral dose of approximately 4 mg kg −1 (range 3.8-3.9 mg kg −1 ), and toxicity assessment was performed while they received the same dose at 21-day intervals.
Zebularine PK
PK results are summarized in Table 1 , and zebularine concentration versus time curves are shown in Figure 1 . Following an oral dose of 8 mg kg −1 , the mean t max was 1.2 ± 0.62 h, mean t 1/2 was 5.7 ± 0.84 h, mean C max was 5280 ± 0.84 ng mL −1 , and mean AUC 0-∞ was 35 358 ± 6132.6 ng mL −1 . Following an oral dose of 4 mg kg −1 , the mean t max was 2.3 ± 1.2 h, mean t 1/2 was 7.1 ± 2.1 h, mean 
Zebularine toxicity -laboratory dogs treated daily with 4 mg kg −1 zebularine
All three laboratory dogs treated with a daily oral zebularine dose of 4 mg kg −1 developed grade 2 (n = 1) or grade 3 (n = 2) neutropenia that progressed to grade 4 neutropenia. Zebularine was discontinued when grade 2 or greater neutropenia was detected on day 14 (n = 1), day 23 (n = 1) and day 24 (n = 1). Neutropenia progressed to grade 4 neutropenia by day 21 (n = 1), day 29 (n = 1) and day 30 (n = 1). Grade 1 thrombocytopenia was detected in one dog. Grade 1 anorexia was detected immediately prior to grade 4 neutropenia in two dogs. No abnormalities were detected in serial serum biochemistry panels or urinalyses. After marked neutropenia developed, supportive care was initiated including antibiotics (n = 3), antiemetics (n = 2) and intravenous crystalloid fluids (n = 2). All three dogs recovered, and neutrophil counts returned to normal within 16, 17 or 19 days, respectively. No abnormalities were detected in serial serum biochemistry panels.
Intermittent dermatologic changes were detected in two laboratory dogs including grade 2 rash/desquamation in the axilla (n = 1) and grade 1 erythema of ventral abdomen (n = 1). Dermatologic changes resolved without specific treatment after zebularine was discontinued.
The laboratory dogs underwent orchiectomy (n = 1) or laparoscopic ovariohysterectomy (n = 2), and had laparoscopic liver and kidney biopsies (n = 3) performed prior to placement in permanent private homes. Specific pathology was not detected in any of the samples that were collected. Liver biopsies revealed nonspecific, mild to moderate, reversible, hepatocellular degeneration in one dog and mild hydropic change in one dog. Renal pathology was not observed.
Zebularine toxicity -tumor bearing dogs treated once every 21 days with 4 mg kg −1 zebularine
Three tumor bearing dogs received six, four and one dose(s) of zebularine, respectively. Grade 1 thrombocytopenia was detected 1 week after the first zebularine treatment in one dog. No dose adjustment was made, and thrombocytopenia did not recur. No other hematologic abnormalities, serum biochemical abnormalities or dermatologic changes were detected. Tumor bearing dogs were removed from the study when there was evidence of tumor progression based on thoracic radiographs and/or ultrasonography or physical examination. In all cases, zebularine was discontinued due to local tumor progression and not due to toxicity. Distant metastasis was not detected in any of the tumor bearing dogs while they were receiving zebularine.
Measurement of aldehyde oxidase activity
Cytosolic aldehyde oxidase activity was measured in 10 dog liver samples by the decrease of benzaldehyde with HPLC. Seven liver samples were collected at necropsy from purpose-bred mixed breed dogs euthanized for an unrelated project, three liver samples were collected via antemortem laparoscopic biopsy from purpose-bred laboratory dogs treated with zebularine, and one liver sample was collected at necropsy from a clinical patient that had not been treated with zebularine. There was insufficient sample from one of the three laboratory dogs for histopathologic evaluation and determination of aldehyde oxidase activity, so the entire sample was used for histopathologic evaluation. As shown in Table 2 , only 2 of 10 canine liver samples had detectable aldehyde oxidase activity (0.193 and 0.116 nmol mg −1 min −1 , respectively). The average aldehyde oxidase activity in rat liver was 0.090 nmol mg −1 min, which was similar to that of the two dogs. In contrast, male mice had the highest liver aldehyde oxidase activity among the three tested species with an average of 1.158 nmol mg −1 min −1 .
Discussion
The purpose of this study was to determine the plasma PK and to assess toxicity of the novel demethylating agent, zebularine, in laboratory and tumor bearing dogs. This work builds upon that previously reported in mice, rats, monkeys, and canine cell lines, and provides pivotal information required for subsequent investigation of zebularine's potential as a demethylating and antineoplastic agent in dogs. 10 -16,18,19 Knowledge of the peak plasma concentrations in dogs can be taken into account when interpreting in vitro and in vivo mechanism studies. The determination that zebularine undergoes constant plasma clearance in the dog and has a mean half-life of 5.7 and 7.1 h in laboratory and tumor bearing dogs, respectively, can be used in designing subsequent treatment studies in dogs. Epigenetic-based treatment strategies can be applied across several cancer types, but work in naturally occurring canine InvTCC is particularly intriguing as it serves as a relevant model of the cancer in humans. Studies in dogs are expected to lead to the development of new treatment strategies that can be applied in both species. 6 The dog study contributed to the understanding of the potential toxicity of zebularine. Following daily treatment with 4 mg kg −1 zebularine, grade 4 neutropenia developed in all three laboratory dogs. Although the myelosuppression resolved after zebularine was discontinued, and all dogs recovered with supportive care, clearly lower zebularine doses are indicated for follow-up studies. The myelosuppression in dogs was not completely unexpected as this has occurred with other demethylating agents in dogs and humans, especially when the drugs are given at higher and potentially cytotoxic doses. 7, 21 The degree of hematologic toxicity at the 4 mg kg −1 dose in dogs, however, was not expected when considering the available published in vivo study results of zebularine in other species. Zebularine was reported to be well tolerated in mice with no significant weight loss or mortality when administered for weeks to months. 11 -15 Although clinicopathologic assessments were not reported in the mouse studies, it would be expected that if severe myelosuppression had occurred, than infection and sepsis would have been noted in the mice. It is also possible that higher doses of zebularine in mice could result in myelosuppression. In male cynomolgus monkeys treated with 5-out of 7-day intravenous infusions of zebularine at <250 mg kg −1 day −1 for two consecutive weeks, an elevation in white blood cell count was observed, although it is not known if the blood counts were performed when the neutropenia would have occurred if it were going to occur at that dosage. Regardless of whether the findings in dogs were expected or not, the documentation of the reversible, yet severe, myelosuppression in dogs is being used in the planning of additional studies of zebularine in dogs. A dose of 4 mg kg −1 every 21 days resulted in no appreciable toxicity in tumor bearing dogs. A follow-up dose escalating trial in dogs with InvTCC is in progress in which the dose intensity of the starting dose cohort (daily 0.2 mg kg −1 zebularine) is equivalent to the dose intensity of 4 mg kg −1 once every 21 days.
The dog study results were encouraging in that major internal organ toxicity was not observed in dogs at any of the doses given. There has been concern for liver and kidney toxicity of zebularine in other species. In male cynomolgus monkeys treated with 5-out of 7-day intravenous infusions at 250 mg kg −1 day −1 of zebularine for two consecutive weeks, clinicopathologic changes included elevated alanine aminotransferase (ALT), lactate dehydrogenase (LDH) and creatine kinase (CK). Higher zebularine doses of 500, 750 or 1000 mg kg −1 given by continuous infusion or bolus resulted in lethal toxicity. 17 Zebularine plasma concentrations rapidly increased prior to death in the cynomolgus monkeys treated with very high dose zebularine, raising the possibility that liver or renal injury could have resulted in decreased zebularine clearance. 17 While LDH and CK were not assessed in the current dog study, serum biochemistry panels did not reveal any evidence of liver or kidney injury following zebularine treatment. Evaluation of post-treatment liver and kidney biopsies did not reveal any specific pathologic changes. Differences in aldehyde oxidase activity or other not-yet-characterized enzymes involved in the metabolism of zebularine could account for variation in drug metabolism, efficacy and toxicity across species and individuals. 3, 22, 23 While a role for aldehyde oxidase in zebularine's toxicity has been posited in other species, the role of aldehyde oxidase in zebularine's toxicity in the dog has not yet been defined. The purpose of the assay described in this study was to determine the aldehyde oxidase activity in samples collected from dogs. In this study, minimal aldehyde oxidase activity was detected in dogs and was only detectable in hepatic cytosol from two dogs that had not been treated with zebularine (see Table 2 ). These findings are similar to results published in previous studies investigating aldehyde oxidase activity, which suggests that aldehyde oxidase activity is low in the dog. 24 -27 There are multiple possible explanations for the limited detection of aldehyde oxidase activity in dogs described in this study. The first being that aldehyde oxidase activity is low in the dog. This conclusion would be consistent with a previous study in which aldehyde oxidase activity was highest in male mice and not detectable in hepatic cytosol from a male Beagle dog. 24 Another possible explanation for the limited detection is that aldehyde oxidase activity may vary widely between individual dogs or breeds of dogs. Aldehyde oxidase activity was not detected in a female Beagle dog, but was detected in a female Greyhound and a male mixed breed dog. The number of samples evaluated and small numbers of breeds represented was insufficient to draw any conclusions about the influence of breed on aldehyde oxidase activity. Evaluation of samples from a larger number of dogs of a variety of breeds and mixed lineages would be required to determine if breed plays any role on aldehyde oxidase activity in the dog. Another possible explanation is that aldehyde oxidase may be more labile in the dog than in other species and may have been degraded to some extent before the assay was performed. Liver samples from dogs, mice and rats in this study were handled and stored in a virtually identical manner, but while aldehyde oxidase activity was detectable in all of the rodent samples it was detectable in just 2 of 10 canine samples. This pattern would be expected if canine aldehyde oxidase was more susceptible to degradation than mouse or rat aldehyde oxidase, but could also be encountered if canine aldehyde oxidase activity is actually low. The metabolism (or lack thereof) of zebularine by enzymes including aldehyde oxidase would be expected to be a key factor in zebularine's anti-tumor effects, as well as its toxicity. The effect of differential aldehyde oxidase activity has been suggested to account, at least in part, for differences in the effects of zebularine on tumor development between female Min mice and male Min mice. These mice harbor a defect in the adenomatous polyposis coli (APC) gene that leads to development of benign intestinal adenomas. 16 In a previous study, a 50-fold increase was detected in aldehyde oxidase activity in male mice compared with female mice, but a similar magnitude of difference was not detected between sexes in rats or humans. 24 The number of tumors that developed in female, but not male, Min mice significantly decreased following treatment with zebularine. In Min mice, there were no reported sex differences in zebularine toxicity. 16 If aldehyde oxidase activity in the dog is low, like in female mice, this could contribute to greater anti-tumor activity of zebularine in the dog. Further investigation of dogs undergoing treatment with zebularine are warranted to determine if aldehyde oxidase activity has a role in zebularine's metabolism and toxicity in the dog. However, due to the nature of the assay described in this study and the invasive sampling technique required (e.g., liver biopsy), investigation of aldehyde oxidase activity antemortem in pet dogs may be limited. While tumor response was not a primary end point of this study, and a very small tumor bearing cohort of dogs was evaluated, it was noted that the two dogs with InvTCC treated with zebularine had stable disease as determined by ultrasonography and thoracic radiographs (<50% change in tumor size and no new lesions) when treated with zebularine once every 21 days for 12-18 weeks. In dogs that have failed therapy with progressive disease, InvTCC often progresses rapidly, and lack of progression over 3-4 months suggests beneficial drug activity. In addition, when considering that the optimal dosing strategy for demethylating agents is likely daily administration 7, 9 , the dosing strategy employed in tumor bearing dogs was unlikely to reflect the optimum benefit that could be gained from zebularine. It is also important to note that the demethylating effects of zebularine could occur at doses considerably lower than those which were toxic in dogs. 3 Based on the mean measured half-life of 5.7 and 7.1 h in laboratory and tumor bearing dogs, respectively, oral dosing once every 24 h would be expected to provide at least a low level of zebularine exposure for most of a 24-h period. In order to inhibit DNA methylation, metabolites of zebularine must be incorporated into DNA and then bind DNMT. The half-life of zebularine metabolites that are incorporated into DNA has been investigated in vitro in human cell lines, but has not been investigated in the dog. 28 Further investigation would be required to determine how long these metabolites persist in the dog, which may be important in determining an optimal dosing interval.
In summary, this study provided important information concerning the PK and toxicity of zebularine in dogs. A daily dose of zebularine of 4 mg kg −1 resulted in unacceptable, but reversible, hematologic toxicity in laboratory dogs while a dose of 4 mg kg −1 every 21 days resulted in no appreciable toxicity in tumor bearing dogs. A dose escalating trial of zebularine at a starting dose of 0.2 mg kg −1 day −1 , which is equivalent to the dose intensity of 4 mg kg −1 once every 21 days used in this study, is currently ongoing in pet dogs with InVTCC. Continued investigation of zebularine is warranted in tumor bearing dogs to determine the optimal dosing strategy, activity as both a single agent and in combination with other drugs and characterization of its demethylating activity in vivo.
